Apricus Biosciences Announces Podium Presentation Of Femprox(R) Phase III Clinical Data At 2012 World Meeting On Sexual Medicine

SAN DIEGO, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( www.apricusbio.com) today announced a podium presentation titled, "Updated analyses of a randomized, double-blind, Phase 3 study of Femprox®, an alprostadil cream with a novel transdermal delivery technology (NexACT®) for the treatment of female sexual arousal disorder (FSAD)," will take place on Monday, August 27, 2012, at 4:30 p.m. CT, as part of the 2012 World Meeting on Sexual Medicine, which is being held August 26-30, 2012 in Chicago.

The presentation will discuss an updated analysis of the approximately 400-women Phase III clinical trial conducted by Apricus Bio to provide further evidence of the statistically significant efficacy and safety profile of Apricus Bio's investigational drug, Femprox® (topical alprostadil 0.4 % cream), for the treatment of FSAD in pre- and post-menopausal women.

The data will be presented by Dr. Irwin Goldstein, Director of Sexual Medicine at the Alvarado Hospital in San Diego, and a member of Apricus Bio's Femprox® Clinical Advisory Board. Dr. Goldstein is the Editor of The Journal of Sexual Medicine, a member of numerous sexual medicine societies, the author or co-author of approximately 260 peer-reviewed papers, and an expert in the area of women's sexual health.

About Femprox ^®

Femprox® is an alprostadil-based 0.4% topical cream intended for the treatment of FSAD. Apricus Bio has completed nine clinical studies to date, including one, 98-patient Phase II study in the U.S. and a near 400-patient Phase III study in China.

It is the Company's understanding that no product is currently approved in the U.S. for FSAD, a persistent or recurring inability to attain, or maintain adequate sexual excitement, causing personal distress.

Femprox® exerts a local, relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow.  The resultant increase in lubrication and sensory feedback is believed to produce a clinically significant increase in sexual arousal in women with FSAD.

1 2 Next › Last »